VP

Venkatesan Prema

Active Director Director DIN 10900786
DIN 10900786 First appointment Jan 2025
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2025
Shareholding value •••• Premium profile

About Venkatesan Prema

Data last updated:

Venkatesan Prema is a Director at Amerlim Biotech Private Limited (since 2025). Amerlim Biotech Private Limited reported revenue of ₹4.4 Lakh (FY 2024).

DIN 10900786
Primary Designation Director
First Appointment 03 Jan 2025
Oldest Company Age 3 yrs
Largest company Amerlim Biotech Private Limited · ₹4.4 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Amerlim Biotech Private Limited U46901TN2023PTC158714
Director03 Jan 20252023₹4.4 Lakh (FY 2024)Active

Board colleagues of Venkatesan Prema

NameDINCompanyDesignation
Sivagnanam Madesh Kumar10065603Amerlim Biotech Private LimitedDirector

Directorship timeline

Open interactive timeline →
Amerlim Biotech Private Limited
Premium access

Shareholding and investment profile for Venkatesan Prema

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Venkatesan Prema

Venkatesan Prema currently holds 1 directorship: Amerlim Biotech Private Limited (Director, since 03 Jan 2025, revenue ₹4.4 Lakh (FY 2024)).

Venkatesan Prema was first appointed on 03 Jan 2025 as Director at Amerlim Biotech Private Limited.

The current boards of Venkatesan Prema's companies include Sivagnanam Madesh Kumar (Amerlim Biotech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available